1. Home
  2. IROQ vs SPRO Comparison

IROQ vs SPRO Comparison

Compare IROQ & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IROQ
  • SPRO
  • Stock Information
  • Founded
  • IROQ 1883
  • SPRO 2013
  • Country
  • IROQ United States
  • SPRO United States
  • Employees
  • IROQ N/A
  • SPRO N/A
  • Industry
  • IROQ Savings Institutions
  • SPRO Biotechnology: Pharmaceutical Preparations
  • Sector
  • IROQ Finance
  • SPRO Health Care
  • Exchange
  • IROQ Nasdaq
  • SPRO Nasdaq
  • Market Cap
  • IROQ 60.4M
  • SPRO 62.7M
  • IPO Year
  • IROQ 2011
  • SPRO 2017
  • Fundamental
  • Price
  • IROQ $21.18
  • SPRO $1.19
  • Analyst Decision
  • IROQ
  • SPRO Buy
  • Analyst Count
  • IROQ 0
  • SPRO 3
  • Target Price
  • IROQ N/A
  • SPRO $5.00
  • AVG Volume (30 Days)
  • IROQ 3.2K
  • SPRO 468.8K
  • Earning Date
  • IROQ 11-04-2024
  • SPRO 11-14-2024
  • Dividend Yield
  • IROQ 1.88%
  • SPRO N/A
  • EPS Growth
  • IROQ N/A
  • SPRO N/A
  • EPS
  • IROQ 0.62
  • SPRO 0.06
  • Revenue
  • IROQ $22,441,000.00
  • SPRO $106,455,000.00
  • Revenue This Year
  • IROQ N/A
  • SPRO N/A
  • Revenue Next Year
  • IROQ N/A
  • SPRO N/A
  • P/E Ratio
  • IROQ $34.15
  • SPRO $19.77
  • Revenue Growth
  • IROQ N/A
  • SPRO 37.01
  • 52 Week Low
  • IROQ $14.00
  • SPRO $1.01
  • 52 Week High
  • IROQ $22.00
  • SPRO $1.89
  • Technical
  • Relative Strength Index (RSI)
  • IROQ 52.32
  • SPRO 41.49
  • Support Level
  • IROQ $21.00
  • SPRO $1.28
  • Resistance Level
  • IROQ $21.36
  • SPRO $1.22
  • Average True Range (ATR)
  • IROQ 0.25
  • SPRO 0.07
  • MACD
  • IROQ -0.09
  • SPRO -0.01
  • Stochastic Oscillator
  • IROQ 61.74
  • SPRO 32.73

About IROQ IF Bancorp Inc.

IF Bancorp Inc is a holding company. It is mainly engaged in the business of directing, planning, and coordinating the business activities of Iroquois Federal. The company with the association take deposits from the general public and invest those deposits together with funds generated from operations and borrowings in various loans such as multi-family residential and mortgage loans, commercial real estate loans, home equity lines of credit, consumer loans, others, and also a variety of deposit accounts and alternative delivery channels.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: